CATX · Perspective Therapeutics, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 17, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients enrolled with lapemelanotide zapixetar (VMT01) | 27 | as of July 31, 2026 | — |
| patients treated with bamzireotide navoxetan (VMT-α-NET) | 76 | as of July 31, 2026 | — |
| patients treated with PSV359 | 17 | as of July 31, 2026 | — |
| Cash, cash equivalents, and short-term investments | 271M | Q1 2026 | — |
| Net proceeds from underwritten offering of securities | 164M | Q1 2026 | — |
| Shares of common stock outstanding | 114M | Q1 2026 | — |
| Warrants and options to purchase shares of common stock outstanding | 20.5M | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CATX
this stock
Perspective Therapeutics, Inc.
|
$366.43M | +20.0% | — | — | 20.6% |
|
ABT
Abbott Laboratories
|
$198.81B | -6.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$119.47B | -3.9% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -47.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 17, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CATX | +3.1% | +13.4% | -38.3% | +13.4% | +20.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.1% | +10.1% | -49.5% | +11.3% | +8.2% |